newsfilter
← Latest News
ACCESS Newswire·

Protagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114

A potential major step toward treating stress-related neuro-psychiatric disordersNEW YORK, NY / ACCESSWIRE / September 26, 2023 / Today, Protagenic Therapeutics, Inc. , a pioneering biopharmaceutical